Scholars@Duke
Georgia Marie Beasley

Georgia Marie Beasley

Associate Professor of Surgery
Surgical Oncology
georgia.beasley@duke.edu
Erwin Rd, Durham, NC 27710
Dept of Surgery, Durham, NC 27710

Selected Publications

RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE).

Journal Article J Clin Oncol · July 8, 2025 PURPOSE: Effective treatment options for melanoma after immune checkpoint blockade failure are limited. RP1 (vusolimogene oderparepvec) is a herpes simplex virus type 1-based oncolytic immunotherapy, here evaluated in combination with nivolumab in anti-PD- ... Full text Link to item Cite

Management of In-transit Disease: Regional Therapies, Intralesional Therapies, and Systemic Therapy.

Journal Article Surg Oncol Clin N Am · July 2025 In-transit (IT) melanoma represents a distinct, heterogeneous pattern of disease that arises as superficial tumors along the track between the primary site and the draining regional lymph node basin. Many therapies have been explored for treatment of this ... Full text Link to item Cite

Circulating Tumor DNA in High-Risk Stage II/III Cutaneous Melanoma: A Feasibility Study.

Journal Article Ann Surg Oncol · July 2025 BACKGROUND: Adjuvant therapies reduce recurrence in patients with clinical stage IIB/IIC/III melanoma; however, better risk stratification and patient selection are needed. Circulating tumor DNA (ctDNA) as a marker of micrometastatic residual disease is be ... Full text Link to item Cite

An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma.

Journal Article Ann Surg Oncol · July 2025 BACKGROUND: Metastatic uveal melanoma (mUM) has a poor prognosis, with liver metastases typically presenting a therapeutic challenge. Melphalan/Hepatic Delivery System (Melphalan/HDS) is a drug/medical device combination used for liver-directed treatment o ... Full text Link to item Cite

Adjuvant Therapy for Melanoma.

Journal Article Surg Clin North Am · June 2025 In recent years, effective systemic therapies have emerged for patients with metastatic melanoma. These therapies have also made their way to the perioperative setting, demonstrating improved recurrence-free survival for subsets of individuals with stage I ... Full text Link to item Cite

Updates in Cutaneous Oncology.

Journal Article Surg Clin North Am · June 2025 Full text Link to item Cite

GLI2 Facilitates Tumor Immune Evasion and Immunotherapeutic Resistance by Coordinating WNT and Prostaglandin Signaling.

Journal Article Cancer Res · May 2, 2025 Therapeutic resistance to immune checkpoint blockade has been commonly linked to the process of mesenchymal transformation (MT) and remains a prevalent obstacle across many cancer types. An improved mechanistic understanding for MT-mediated immune evasion ... Full text Link to item Cite

National Trends in Management of the Nodal Basin for Pediatric Patients With Occult Stage III Melanoma in the United States.

Journal Article Pediatr Blood Cancer · May 2025 BACKGROUND: Following the publication of recent trials (MSLT-I, MSLT-II, DeCOG), routine completion lymph node dissection (CLND) after positive sentinel lymph node biopsy (SLNB) is no longer recommended for adults with melanoma, while adjuvant immunotherap ... Full text Link to item Cite

Opportunities for Discovery Using Neoadjuvant Immune Checkpoint Blockade in Melanoma.

Journal Article Int J Mol Sci · March 8, 2025 Treatment of resectable advanced-stage melanoma with neoadjuvant immunotherapy is rapidly becoming the new standard of care due to significant improvements in event-free survival (EFS) compared to surgery first followed by immunotherapy. The level of respo ... Full text Link to item Cite

Impact of Social Determinants of Health on Melanoma Nodal Surveillance in a Multi-institutional Cohort.

Conference Ann Surg Oncol · March 2025 BACKGROUND: Nodal surveillance (NS) has overtaken completion lymphadenectomy as the preferred management for sentinel node-positive (SLN+) melanoma, but requires frequent exams and nodal ultrasound (US). Social determinants of health (SDoH) may affect US a ... Full text Link to item Cite

Neoadjuvant therapy for melanoma: past, present, and future.

Journal Article Surg Oncol · October 2024 Modern systemic therapy has dramatically improved outcomes for many patients with advanced metastatic melanoma. The success of these therapies has attracted much scientific interest while these therapies have made their way into the treatment of earlier st ... Full text Link to item Cite

Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.

Journal Article Ann Surg Oncol · August 2024 BACKGROUND: Uveal melanoma (UM) has a poor prognosis once liver metastases occur. The melphalan/Hepatic Delivery System (melphalan/HDS) is a drug/device combination used for liver-directed treatment of metastatic UM (mUM) patients. The purpose of the FOCUS ... Full text Link to item Cite

A lactate-SREBP2 signaling axis drives tolerogenic dendritic cell maturation and promotes cancer progression.

Journal Article Sci Immunol · May 10, 2024 Conventional dendritic cells (DCs) are essential mediators of antitumor immunity. As a result, cancers have developed poorly understood mechanisms to render DCs dysfunctional within the tumor microenvironment (TME). After identification of CD63 as a specif ... Full text Link to item Cite

Gli2 Facilitates Tumor Immune Evasion and Immunotherapeutic Resistance by Coordinating Wnt Ligand and Prostaglandin Signaling.

Journal Article bioRxiv · April 1, 2024 UNLABELLED: Therapeutic resistance to immune checkpoint blockade has been commonly linked to the process of mesenchymal transformation (MT) and remains a prevalent obstacle across many cancer types. An improved mechanistic understanding for MT-mediated imm ... Full text Link to item Cite

Articles from 2022 to 2023 to Inform Your Cancer Practice: Melanoma.

Journal Article Ann Surg Oncol · March 2024 Modern effective systemic therapy for melanoma includes two important classes of treatment: immune checkpoint inhibitors (ICIs), comprising inhibitors of cytotoxic T-lymphocyte antigen 4, programmed cell death receptor 1, and lymphocyte-activation gene 3; ... Full text Link to item Cite

At the Intersection of Intersectionality: Race and Gender Diversity Among Surgical Faculty and Trainees.

Journal Article Ann Surg · January 1, 2024 OBJECTIVE: To compare the representation of intersectional (ie, racial/ethnic and gender) identities among surgical faculty versus medical students. BACKGROUND: Health disparities are pervasive in medicine, but diverse physicians may help the medical profe ... Full text Link to item Cite

Whole Transcriptome Profiling of Patients with In Transit Melanoma

Conference ANNALS OF SURGICAL ONCOLOGY · 2024 Cite

Melanin imaging with pump-probe microscopy for diagnosis of metastatic melanoma

Conference 2024 Conference on Lasers and Electro-Optics, CLEO 2024 · January 1, 2024 Melanoma, the most aggressive skin cancer, is responsible for around 10,000 deaths annually.Wearedevelopingadiagnosticbiomarkerbasedonfemtosecondpump-probemicroscopy of melanin, a natural pigment found in most melanoma. ... Cite

Melanin imaging with pump-probe microscopy for diagnosis of metastatic melanoma

Conference 2024 Conference on Lasers and Electro Optics CLEO 2024 · January 1, 2024 Melanoma, the most aggressive skin cancer, is responsible for around 10,000 deaths annually.Wearedevelopingadiagnosticbiomarkerbasedonfemtosecondpump-probemicroscopy of melanin, a natural pigment found in most melanoma. ... Full text Cite

Racial, Ethnic, and Gender Diversity Among Academic Surgical Leaders in the US.

Journal Article JAMA Surg · December 1, 2023 IMPORTANCE: Surgical department chairs remain conspicuously nondiverse despite the recognized importance of diverse physician workforces. However, the extent of diversity among non-chair leadership remains underexplored. OBJECTIVE: To evaluate racial, ethn ... Full text Link to item Cite

ASO Author Reflections: It's About Time?

Journal Article Ann Surg Oncol · October 2023 Full text Link to item Cite

Timing of Adjuvant Immunotherapy in Stage III Melanoma, Does it Matter?

Journal Article Ann Surg Oncol · October 2023 BACKGROUND: The optimal time to initiate adjuvant immune checkpoint inhibitors (ICI) following resection remains undefined. Herein, we investigated the impact of time to adjuvant ICI on survival in patients with stage III melanoma. METHODS: Patients with r ... Full text Link to item Cite

Survey Study of Clerkship Curriculum on Learner's Choice to Pursue Surgery: Positive Impact of Extracurricular Opportunities.

Journal Article J Surg Educ · September 2023 OBJECTIVE: Prior studies have focused on the role of the learning environment on students' decisions to pursue surgery, but few have analyzed the impact of the clerkship curriculum. This study assessed surgical clerkship curricula across United States (US) ... Full text Link to item Cite

LASSO and Elastic Net Tend to Over-Select Features

Journal Article Mathematics · September 1, 2023 Machine learning methods have been a standard approach to select features that are associated with an outcome and to build a prediction model when the number of candidate features is large. LASSO is one of the most popular approaches to this end. The LASSO ... Full text Cite

Multicenter Experience with Neoadjuvant Therapy in Melanoma Highlights Heterogeneity in Contemporary Practice.

Journal Article Ann Surg · June 1, 2023 OBJECTIVE: To determine the feasibility and impact of neoadjuvant therapy (NT) in patients who present with advanced melanoma amenable to surgical resection. SUMMARY BACKGROUND DATA: Given current effective systemic therapy for melanoma, the use of NT is b ... Full text Link to item Cite

Initial efficacy and safety of RP1 + nivolumab in patients with anti–PD-1–failed melanoma from the ongoing phase 1/2 IGNYTE study.

Conference Journal of Clinical Oncology · June 1, 2023 9509 Background: Patients (pts) with melanoma who progress on anti–PD-1 therapy (anti–PD-1–failed) have limited treatment options. RP1 is an HSV-1–based oncolytic immunotherapy expressing human GM-CSF and a fusogenic protein (GAL ... Full text Cite

Patient-derived skin MicroOrganoSpheres and clinical response to immunotherapy.

Conference Journal of Clinical Oncology · June 1, 2023 2588 Background: Immunotherapies, including immune checkpoint inhibitors (ICI), have revolutionized the treatment of many cancers, producing significant improvements in survival in patients with many different cancers. However, t ... Full text Cite

A phase 1 first-in-human study of interferon beta (IFNβ) and membrane-stable CD40L expressing oncolytic virus (MEM-288) in solid tumors including non–small-cell lung cancer (NSCLC).

Conference Journal of Clinical Oncology · June 1, 2023 2569 Background: MEM-288 is a conditionally-replicative oncolytic adenovirus expressing human IFNβ and a recombinant membrane-stable form of CD40L (MEM40). Preclinical studies show MEM-288 induces robust dendritic cell-mediated s ... Full text Cite

International Center-Level Variation in Utilization of Completion Lymph Node Dissection and Adjuvant Systemic Therapy for Sentinel Lymph Node-Positive Melanoma at Major Referral Centers.

Journal Article Ann Surg · May 1, 2023 OBJECTIVE: The aim of this study was to determine overall trends and center-level variation in utilization of completion lymph node dissection (CLND) and adjuvant systemic therapy for sentinel lymph node (SLN)-positive melanoma. SUMMARY BACKGROUND DATA: Ba ... Full text Link to item Cite

Survival and tumor characteristics of patients presenting with single primary versus second primary melanoma lesions.

Journal Article J Am Acad Dermatol · May 2023 BACKGROUND: Patients with single primary melanomas have an increased risk of developing subsequent melanomas. Secondary tumors diagnosed within and after 3 months are termed "synchronous" and "asynchronous," respectively. OBJECTIVE: To compare tumor distri ... Full text Link to item Cite

Abstract CT053: Merlin_001: a prospective registry study of a primary melanoma gene-signature to predict sentinel node (SN) status and determine its prognostic value for more accurate staging of SN-negative melanoma patients

Conference Cancer Research · April 14, 2023 AbstractBackground: Sentinel lymph node biopsy (SLNB) provides important staging and prognostic information that guides surveillance and adjuvant systemic therapy decisions for patients with cutaneous melano ... Full text Cite

Abstract CT103: A phase 1 first-in-human study of MEM-288 oncolytic virus in solid tumors including non-small cell lung cancer (NSCLC): impact on tumor and systemic T cell immunity

Conference Cancer Research · April 14, 2023 AbstractBackground: MEM-288 is a conditionally-replicative oncolytic adenovirus expressing human IFNβ and a recombinant membrane-stable form of CD40L (MEM40). Preclinical studies show MEM-288 induces robust ... Full text Cite

Abstract 2892: A SREBF2-dependent genetic program drives a novel immunotolerant dendritic cell population that supports cancer progression

Journal Article Cancer Research · April 4, 2023 AbstractThe development of immune responses to cancers are crucially dependent upon effective antigen cross-presentation by local dendritic cell (DC) populations. Indeed, DC-mediated T cell stimulation is es ... Full text Cite

Intratumor childhood vaccine-specific CD4+ T-cell recall coordinates antitumor CD8+ T cells and eosinophils.

Journal Article J Immunother Cancer · April 2023 BACKGROUND: Antitumor mechanisms of CD4+ T cells remain crudely defined, and means to effectively harness CD4+ T-cell help for cancer immunotherapy are lacking. Pre-existing memory CD4+ T cells hold potential to be leveraged for this purpose. Moreover, the ... Full text Link to item Cite

Data from Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma

Other · March 31, 2023 <div>AbstractPurpose:<p>In this prospective trial, we sought to assess the feasibility of concurrent administration of ipilimumab and radiation as adjuvant, neoadjuvant, or definitive therapy in patients with regionally advanced melanom ... Full text Cite

Data from Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma

Other · March 31, 2023 <div>AbstractPurpose:<p>In this prospective trial, we sought to assess the feasibility of concurrent administration of ipilimumab and radiation as adjuvant, neoadjuvant, or definitive therapy in patients with regionally advanced melanom ... Full text Cite

Regional control after precision lymph node dissection for clinically evident melanoma metastasis.

Journal Article J Surg Oncol · January 2023 INTRODUCTION: Completion lymph node dissection (CLND) for microscopic lymph node metastases has been replaced by observation; however, CLND is standard for clinically detectable nodal metastases (cLN). CLND has high morbidity, which may be reduced by excis ... Full text Link to item Cite

Clinical Trials in Melanoma: Margins, Lymph Nodes, Targeted and Immunotherapy.

Journal Article Surg Oncol Clin N Am · January 2023 Multiple randomized controlled trials have influenced the current standard of care for patients with cutaneous melanoma. Since the development of targeted and immune therapy, studies of adjuvant therapy for patients with resected stage III/IV melanoma have ... Full text Link to item Cite

Functional reprogramming of peripheral blood monocytes by soluble mediators in patients with pancreatic cancer and intraductal papillary mucinous neoplasms.

Journal Article Front Immunol · 2023 BACKGROUND: Monocytes and monocyte-derived tumor infiltrating cells have been implicated in the immunosuppression and immune evasion associated with pancreatic adenocarcinoma (PDAC). Yet, precisely how monocytes in the periphery and tumor microenvironment ... Full text Link to item Cite

Tumor-intrinsic NLRP3-HSP70-TLR4 axis drives premetastatic niche development and hyperprogression during anti-PD-1 immunotherapy.

Journal Article Sci Transl Med · November 23, 2022 The tumor-intrinsic NOD-, LRR- and pyrin domain-containing protein-3 (NLRP3) inflammasome-heat shock protein 70 (HSP70) signaling axis is triggered by CD8+ T cell cytotoxicity and contributes to the development of adaptive resistance to anti-programmed cel ... Full text Link to item Cite

Examining the role of wide excision margins in pediatric melanoma: A National Cancer Database analysis.

Journal Article Pediatr Blood Cancer · November 2022 BACKGROUND: Although adult guidelines are often applied to children, age-specific surgical margins have not been defined for pediatric melanoma. PROCEDURE: Patients <20 years of age with invasive, cutaneous melanoma were identified using the 2004-2016 N ... Full text Link to item Cite

An Internally Validated Prognostic Risk-Score Model for Disease-Specific Survival in Clinical Stage I and II Merkel Cell Carcinoma.

Journal Article Ann Surg Oncol · October 2022 BACKGROUND: Merkel cell carcinoma (MCC) is a rare cutaneous malignancy for which factors predictive of disease-specific survival (DSS) are poorly defined. METHODS: Patients from six centers (2005-2020) with clinical stage I-II MCC who underwent sentinel ly ... Full text Link to item Cite

Oncologic Outcomes of Multi-Institutional Minimally Invasive Inguinal Lymph Node Dissection for Melanoma Compared with Open Inguinal Dissection in the Second Multicenter Selective Lymphadenectomy Trial (MSLT-II).

Journal Article Ann Surg Oncol · September 2022 BACKGROUND: Minimally invasive inguinal lymphadenectomy (MILND) is safe and feasible, but limited data exist regarding oncologic outcomes. METHODS: This study performed a multi-institutional retrospective cohort analysis of consecutive MILND performed for ... Full text Link to item Cite

Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanoma.

Journal Article J Immunother Cancer · September 2022 BACKGROUND: We previously reported results from a phase 1 study testing intratumoral recombinant poliovirus, lerapolturev, in 12 melanoma patients. All 12 patients received anti-PD-1 systemic therapy before lerapolturev, and 11 of these 12 patients also re ... Full text Link to item Cite

Contrast mechanisms in pump-probe microscopy of melanin.

Journal Article Opt Express · August 29, 2022 Pump-probe microscopy of melanin in tumors has been proposed to improve diagnosis of malignant melanoma, based on the hypothesis that aggressive cancers disaggregate melanin structure. However, measured signals of melanin are complex superpositions of mult ... Full text Open Access Link to item Cite

Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection.

Journal Article J Immunother Cancer · August 2022 Until recently, most patients with sentinel lymph node-positive (SLN+) melanoma underwent a completion lymph node dissection (CLND), as mandated in published trials of adjuvant systemic therapies. Following multicenter selective lymphadenectomy trial-II, m ... Full text Link to item Cite

Predictive factors of neoadjuvant immune checkpoint blockade in melanoma.

Journal Article Hum Vaccin Immunother · May 31, 2022 This review describes the current body of literature and ongoing clinical trials examining neoadjuvant immune checkpoint inhibitors (ICI) for patients with resectable stage III and IV melanoma. Based on prior success in treating metastatic melanoma and as ... Full text Link to item Cite

How much time is enough? Sentinel lymph node mapping time depends on the radiotracer agent.

Journal Article J Surg Oncol · March 2022 BACKGROUND: In 2014, technetium-99m tilmanocept (TcTM) replaced technetium-99m sulfur colloid (TcSC) as the standard lymphoscintigraphy (LS) mapping agent in melanoma patients undergoing sentinel lymph node biopsy (SLNB). The aim of this study was to exami ... Full text Link to item Cite

Oncolytic viruses in melanoma.

Journal Article Front Biosci (Landmark Ed) · February 14, 2022 Malignant melanoma recurrence remains heterogeneous in presentation, ranging from locoregional disease (i.e., local recurrence, satellites, in transit disease) to distant dermal and visceral metastases. This diverse spectrum of disease requires a personali ... Full text Link to item Cite

Melanoma trials that defined surgical management: Overview of trials that established NCCN margin guidelines.

Journal Article J Surg Oncol · January 2022 Since the observation that clearance of all visible and microscopic tumors from cutaneous melanoma is critical to prevent a recurrence, wide surgical margins have been central to surgical dogma. In the last several decades, more conservative margin widths ... Full text Link to item Cite

In-transit Melanoma: A Multi-institutional Analysis of Outcomes

Conference ANNALS OF SURGICAL ONCOLOGY · 2022 Cite

Spatial biology analysis reveals B cell follicles in secondary lymphoid structures may regulate anti-tumor responses at initial melanoma diagnosis.

Journal Article Front Immunol · 2022 INTRODUCTION: B cells are key regulators of immune responses in melanoma. We aimed to explore differences in the histologic location and activation status of B cell follicles in sentinel lymph nodes (SLN) of melanoma patients. METHODS: Flow cytometry was p ... Full text Link to item Cite

Improved survival of multiple vs single primary melanomas

Conference JOURNAL OF INVESTIGATIVE DERMATOLOGY · 2022 Cite

Melanoma

Chapter · January 1, 2022 The treatment landscape for melanoma has dramatically changed in the last 9 years. The application of checkpoint blockade therapy and targeted therapies has driven improvements in survival for many patients with metastatic melanoma. Here, we review common ... Full text Cite

Melanoma lymph node metastases - moving beyond quantity in clinical trial design and contemporary practice.

Journal Article Front Oncol · 2022 The presence of lymph node metastases is a well-studied prognostic factor for cutaneous melanoma. Characterization of melanoma lymph node metastases and their association with survival in multiple, large observational studies has led to recognition of the ... Full text Link to item Cite

The Role of Surgery in Managing Primary and Metastatic Melanoma

Chapter · January 1, 2022 This chapter describes updates in the surgical management of melanoma including primary melanoma, regional melanoma, and distant metastatic disease. Surgical management is discussed in the context of a multidisciplinary approach. Specifically, surgical the ... Full text Cite

Trends in Racial, Ethnic, and Sex Representation Among Surgical Faculty Members and Medical Students in the US, 2011-2020.

Journal Article JAMA Surg · December 1, 2021 This cohort study uses existing data on race, ethnicity, and sex among US surgical faculty members and medical students to identify changes between 2011 and 2020. ... Full text Link to item Cite

Predictors of False Negative Sentinel Lymph Node Biopsy in Clinically Localized Merkel Cell Carcinoma.

Journal Article Ann Surg Oncol · November 2021 BACKGROUND: Sentinel lymph node biopsy (SLNB) is routinely recommended for clinically localized Merkel cell carcinoma (MCC); however, predictors of false negative (FN) SLNB are undefined. METHODS: Patients from six centers undergoing wide excision and SLNB ... Full text Link to item Cite

Potential Utility of Synthetic D-Lactate Polymers in Skin Cancer.

Journal Article JID Innov · September 2021 Increased breakdown of glucose through glycolysis in both aerobic and anaerobic conditions is a hallmark feature of mammalian cancer and leads to increased production of L-lactate. The high-level lactate present within the tumor microenvironment is reused ... Full text Link to item Cite

Adjuvant Radiation Therapy for Clinical Stage III Melanoma in the Modern Therapeutic Era.

Journal Article Ann Surg Oncol · July 2021 BACKGROUND: Adjuvant radiation therapy (RT) can decrease lymph node basin (LNB) recurrences in patients with clinically evident melanoma lymph node (LN) metastases following lymphadenectomy, but its role in the era of modern systemic therapies (ST), immune ... Full text Link to item Cite

Characterization of Sentinel Lymph Node Immune Signatures and Implications for Risk Stratification for Adjuvant Therapy in Melanoma.

Journal Article Ann Surg Oncol · July 2021 BACKGROUND: Although sentinel lymph node (SLN) biopsy is a standard procedure used to identify patients at risk for melanoma recurrence, it fails to risk-stratify certain patients accurately. Because processes in SLNs regulate anti-tumor immune responses, ... Full text Link to item Cite

Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-2).

Journal Article Cancer · July 1, 2021 BACKGROUND: For patients with sentinel lymph node (SLN)-positive cutaneous melanoma, the Second Multicenter Selective Lymphadenectomy trial demonstrated equivalent disease-specific survival (DSS) with active surveillance using nodal ultrasound versus compl ... Full text Link to item Cite

Isolated same-basin lymph node recurrence after precision lymph node excision for clinically evident melanoma metastasis.

Conference Journal of Clinical Oncology · May 20, 2021 9576 Background: While management of the nodal basin for melanoma has largely moved to observation for microscopic sentinel lymph node (SLN) metastasis, complete lymph node dissection (CLND) remains the current standard of care f ... Full text Cite

Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases: Preliminary results of FOCUS (PHP-OCM-301/301A) phase III trial.

Conference Journal of Clinical Oncology · May 20, 2021 9510 Background: Ocular melanoma, the most common intraocular malignancy, frequently metastasizes to the liver but to date there is no established standard of care for hepatic-dominant ocular melanoma patients. The FOCUS trial be ... Full text Cite

Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy.

Journal Article Cell Rep · May 4, 2021 While immune checkpoint blockade is associated with prolonged responses in multiple cancers, most patients still do not benefit from this therapeutic strategy. The Wnt-β-catenin pathway is associated with diminished T cell infiltration; however, activating ... Full text Open Access Link to item Cite

Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched Analysis.

Journal Article J Am Coll Surg · April 2021 BACKGROUND: In sentinel lymph node (SLN)-positive melanoma, two randomized trials demonstrated equivalent melanoma-specific survival with nodal surveillance vs completion lymph node dissection (CLND). Patients with microsatellites, extranodal extension (EN ... Full text Link to item Cite

Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma.

Journal Article J Immunother Cancer · April 2021 BACKGROUND: While programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) antagonists have improved the prognosis for many patients with melanoma, around 60% fail therapy. PVSRIPO is a non-neurovirulent rhinovirus:poliovirus chimera th ... Full text Link to item Cite

Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling.

Journal Article Nat Commun · March 25, 2021 Activating intra-tumor innate immunity might enhance tumor immune surveillance. Virotherapy is proposed to achieve tumor cell killing, while indirectly activating innate immunity. Here, we report that recombinant poliovirus therapy primarily mediates antit ... Full text Link to item Cite

Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma.

Journal Article Clin Cancer Res · March 1, 2021 PURPOSE: In this prospective trial, we sought to assess the feasibility of concurrent administration of ipilimumab and radiation as adjuvant, neoadjuvant, or definitive therapy in patients with regionally advanced melanoma. PATIENTS AND METHODS: Twenty-fou ... Full text Link to item Cite

Dissecting the immune landscape of tumor draining lymph nodes in melanoma with high-plex spatially resolved protein detection.

Journal Article Cancer Immunol Immunother · February 2021 BACKGROUND: In melanoma patients, microscopic tumor in the sentinel lymph-node biopsy (SLN) increases the risk of distant metastases, but the transition from tumor in the SLN to metastatic disease remains poorly understood. METHODS: Fluorescent staining fo ... Full text Link to item Cite

Acral Lentiginous Melanoma: A United States Multi-Center Substage Survival Analysis.

Journal Article Cancer Control · 2021 BACKGROUND: Acral lentiginous melanoma is associated with worse survival than other subtypes of melanoma. Understanding prognostic factors for survival and recurrence can help better inform follow-up care. OBJECTIVES: To analyze the clinicopathologic featu ... Full text Link to item Cite

The Devil's in the Details: Discrepancy Between Biopsy Thickness and Final Pathology in Acral Melanoma.

Conference Ann Surg Oncol · December 2020 PURPOSE: We hypothesized that initial biopsy may understage acral lentiginous melanoma (ALM) and lead to undertreatment or incomplete staging. Understanding this possibility can potentially aid surgical planning and improve primary tumor staging. METHODS: ... Full text Link to item Cite

Adjuvant Therapy is Effective for Melanoma Patients with a Positive Sentinel Lymph Node Biopsy Who Forego Completion Lymphadenectomy.

Journal Article Annals of surgical oncology · December 2020 BackgroundMultiple adjuvant therapies for melanoma have been approved since 2015 based on randomized trials demonstrating improvements in recurrence-free survival (RFS) with adjuvant therapy after surgical resection of high-risk disease. Inclusion ... Full text Cite

Overall Survival Improved for Contemporary Patients with Melanoma: A 2004-2015 National Cancer Database Analysis.

Journal Article Oncol Ther · December 2020 INTRODUCTION: Since 2011, encouraging clinical trial results have led to approval of multiple new therapies for advanced melanoma, but the impact of these therapies outside of trial populations is largely unknown. This study examines use of novel therapies ... Full text Link to item Cite

Oncologic Outcomes After Isolated Limb Infusion for Advanced Melanoma: An International Comparison of the Procedure and Outcomes Between the United States and Australia.

Journal Article Ann Surg Oncol · December 2020 BACKGROUND: Isolated limb infusion (ILI) is a minimally invasive procedure for delivering high-dose chemotherapy to extremities affected by locally advanced or in-transit melanoma. This study compared the outcomes of melanoma patients treated with ILI in t ... Full text Link to item Cite

The utility of initial staging PET-CT as a baseline scan for surveillance imaging in stage II and III melanoma.

Journal Article Surg Oncol · December 2020 BACKGROUND: This study evaluates the utility of whole-body PET-CT for the initial staging and subsequent surveillance imaging of patients with completely resected stage II and stage III melanoma. METHODS: A single-center, retrospective review of patients w ... Full text Link to item Cite

Factors predicting toxicity and response following isolated limb infusion for melanoma: An international multi-centre study.

Conference Eur J Surg Oncol · November 2020 INTRODUCTION: Isolated limb infusion (ILI) is a minimally-invasive procedure for delivering high-dose regional chemotherapy to treat melanoma in-transit metastases confined to a limb. The aim of this international multi-centre study was to identify predict ... Full text Link to item Cite

Retreatment with talimogene laherparepvec for advanced melanoma.

Journal Article Immunotherapy · November 2020 Aim: Talimogene laherparepvec (T-VEC) is a genetically modified oncolytic herpesvirus approved for the treatment of unresectable, locoregionally advanced and recurrent melanoma. There is little relevant literature in the context of retreatment with T-VEC. ... Full text Link to item Cite

Higher BMI, But Not Sarcopenia, Is Associated With Pembrolizumab-related Toxicity in Patients With Advanced Melanoma.

Journal Article Anticancer Res · September 2020 BACKGROUND/AIM: To determine whether BMI and sarcopenia were related to treatment-limiting toxicity or efficacy of pembrolizumab treatment in melanoma patients. PATIENTS AND METHODS: Medical records for melanoma patients undergoing pembrolizumab treatment ... Full text Link to item Cite

Injectable Therapies for Regional Melanoma.

Journal Article Surg Oncol Clin N Am · July 2020 Patients with unresectable cutaneous, subcutaneous, or nodal melanoma metastases are often candidates for injectable therapies, which are attractive for ease of intralesional delivery to superficial metastases and limited systemic toxicity profiles. Inject ... Full text Link to item Cite

Mind the gap: Gendered publication trends in oncology.

Journal Article Cancer · June 15, 2020 BACKGROUND: Investigating scientific publication trends in the field of oncology may highlight opportunities for improved representation, mentorship, collaboration, and advancement for women. METHODS: We conducted a bibliometric analysis of Annals of Surgi ... Full text Link to item Cite

International Multicenter Experience of Isolated Limb Infusion for In-Transit Melanoma Metastases in Octogenarian and Nonagenarian Patients.

Journal Article Ann Surg Oncol · May 2020 BACKGROUND: Isolated limb infusion (ILI) is used to treat in-transit melanoma metastases confined to an extremity. However, little is known about its safety and efficacy in octogenarians and nonagenarians (ON). PATIENTS AND METHODS: ON patients (≥ 80 years ... Full text Link to item Cite

Type of Organ Transplanted Impacts the Risk and Presentation of Cutaneous Squamous Cell Carcinoma in Transplant Recipients.

Journal Article Exp Clin Transplant · February 2020 OBJECTIVES: Transplant immunosuppression increases the risk of cutaneous squamous cell carcinoma by 65- to 200-fold. Our objective was to investigate the impact of the type of organ transplanted on the risk and presentation of cutaneous squamous cell carci ... Full text Link to item Cite

The Landmark Series: Regional Therapy of Recurrent Cutaneous Melanoma.

Journal Article Ann Surg Oncol · January 2020 In-transit melanoma represents a distinct disease pattern in which melanoma recurs as dermal or subcutaneous nodules between the primary melanoma site and the draining regional lymph node basin. The disease pattern is often not amenable to complete surgica ... Full text Link to item Cite

Isolated Limb Infusion for Melanoma

Chapter · January 1, 2020 Isolated limb infusion (ILI) using melphalan and dactinomycin (actinomycin D) was developed as a simplified and minimally invasive alternative to the traditional, more invasive, and elaborative isolated limb perfusion (ILP) to treat unresectable metastatic ... Full text Cite

Efficacy of Talimogene Laherparepvec (T-VEC) Therapy in Patients with In-Transit Melanoma Metastasis Decreases with Increasing Lesion Size.

Conference Ann Surg Oncol · December 2019 BACKGROUND: Talimogene laherparepvec (T-VEC) is the first injectable oncolytic viral therapy approved for in-transit melanoma metastasis, with a reported overall response rate (ORR) of 25% and complete response rate (CRR) of 10%. To ascertain the role of p ... Full text Link to item Cite

Correction to: Characteristics Associated with Pathologic Nodal Burden in Patients Presenting with Clinical Melanoma Nodal Metastasis.

Journal Article Ann Surg Oncol · December 2019 In the original article, there is an error in the funding information. The correct funding information is as follows. ... Full text Link to item Cite

Characteristics Associated with Pathologic Nodal Burden in Patients Presenting with Clinical Melanoma Nodal Metastasis.

Journal Article Ann Surg Oncol · November 2019 BACKGROUND: Nodal observation is safe for patients with microscopic melanoma metastasis in a sentinel lymph node (LN). Complete LN dissection (CLND) remains the standard of care for patients with clinically evident LN (cLN) metastases, even though about 40 ... Full text Link to item Cite

Mind the Gap: Gendered Publication Trends in Academic Oncology

Conference International Journal of Radiation Oncology*Biology*Physics · September 2019 Full text Cite

Correction to: Sentinel Lymph Node Biopsy and Completion Lymph Node Dissection for Melanoma.

Journal Article Curr Treat Options Oncol · August 29, 2019 The original version of this article, which published in Current Treatment Options in Oncology, Volume 19, Issue 11, November 2018, contained an error within the Conflict of Interest statements. It was originally stated that "Norma E. Farrow received suppo ... Full text Link to item Cite

Long-Term Oncologic Outcomes After Isolated Limb Infusion for Locoregionally Metastatic Melanoma: An International Multicenter Analysis.

Conference Ann Surg Oncol · August 2019 BACKGROUND: Isolated limb infusion (ILI) is a minimally invasive procedure for delivering high-dose regional chemotherapy to patients with locally advanced or in-transit melanoma located on a limb. The current international multicenter study evaluated the ... Full text Link to item Cite

The impact of transplant rejection on cutaneous squamous cell carcinoma in renal transplant recipients.

Journal Article Clin Exp Dermatol · April 2019 BACKGROUND: The incidence of cutaneous squamous cell carcinoma (cSCC) is markedly increased in renal transplant recipients compared with that of the nontransplant population. AIM: To investigate whether there is a relationship between transplant rejection ... Full text Link to item Cite

The Emerging Role of Surgery for Patients With Advanced Melanoma Treated With Immunotherapy.

Journal Article J Surg Res · April 2019 BACKGROUND: The emergence of immune checkpoint inhibitors (ICIs) has improved survival for patients with metastatic melanoma. The types of disease-response patterns to ICI therapy can be more complex relative to traditional chemotherapy and include mixed r ... Full text Link to item Cite

Overall Survival Improved for Contemporary Patients with Melanoma

Conference ANNALS OF SURGICAL ONCOLOGY · February 1, 2019 Link to item Cite

Substage-Specific Survival in Acral Lentiginous Melanoma

Conference ANNALS OF SURGICAL ONCOLOGY · February 1, 2019 Link to item Cite

Updates in adjuvant systemic therapy for melanoma.

Journal Article J Surg Oncol · January 2019 There has been a rapid increase in adjuvant therapies approved for treatment following surgical resection of stages III/IV melanoma. We review current indications for adjuvant therapy, which currently includes a heterogenous group of stages III and IV pati ... Full text Link to item Cite

Examining Peripheral and Tumor Cellular Immunome in Patients With Cancer.

Journal Article Front Immunol · 2019 Immunotherapies are rapidly being integrated into standard of care (SOC) therapy in conjunction with surgery, chemotherapy, and radiotherapy for many cancers and a large number of clinical studies continue to explore immunotherapy alone and as part of comb ... Full text Link to item Cite

Sentinel Lymph Node Biopsy and Completion Lymph Node Dissection for Melanoma.

Journal Article Curr Treat Options Oncol · September 19, 2018 This review critically evaluates recent trials which have challenged the practice of completion lymph node dissection (CLND) for melanoma patients diagnosed with regional metastasis by positive sentinel lymph node biopsy (SLNB). Two trials in the last 2 ye ... Full text Link to item Cite

Does the number of sentinel lymph nodes removed affect the false negative rate for head and neck melanoma?

Journal Article J Surg Oncol · June 2018 BACKGROUND AND OBJECTIVES: Head and neck (HN) cutaneous melanoma is associated with worse disease-free survival compared to non-HN cutaneous melanoma, possibly due to inadequate staging. We aim to determine if a higher yield of sentinel lymph nodes (SLNs) ... Full text Link to item Cite

Contemporary Approaches to In-Transit Melanoma.

Journal Article J Oncol Pract · May 2018 In-transit melanoma represents a distinct disease pattern of heterogeneous superficial tumors. Many treatments have been developed specifically for this type of disease, including regional chemotherapy and a variety of directly injectable agents. Novel str ... Full text Link to item Cite

Management of metastatic retroperitoneal sarcoma: a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG).

Journal Article Ann Oncol · April 1, 2018 INTRODUCTION: Retroperitoneal sarcoma (RPS) is a rare disease accounting for 0.1%-0.2% of all malignancies. Management of RPS is complex and requires multidisciplinary, tailored treatment strategies at all stages, but especially in the context of metastati ... Full text Link to item Cite

Metastatic melanoma patients' sensitivity to ipilimumab cannot be predicted by tumor characteristics.

Journal Article Int J Surg Oncol (N Y) · October 2017 UNLABELLED: Immune checkpoint inhibitors have dramatically changed the prognosis for patients with metastatic melanoma. However, not all patients respond to therapy and toxicities can be severe leaving need for reliable clinical predictive markers. METHODS ... Full text Link to item Cite

Sentinel Lymph Node Biopsy for Recurrent Melanoma: A Multicenter Study.

Journal Article Ann Surg Oncol · September 2017 BACKGROUND: Sentinel lymph node biopsy (SLNB) is routinely performed for primary cutaneous melanomas; however, limited data exist for SLNB after locally recurrent (LR) or in-transit (IT) melanoma. METHODS: Data from three centers performing SLNB for LR/IT ... Full text Link to item Cite

Surveillance strategies in the follow-up of melanoma patients: too much or not enough?

Journal Article J Surg Res · June 15, 2017 BACKGROUND: After appropriate initial therapy for patients with stage II-III melanoma, there is no consensus regarding surveillance. Thus, follow-up is highly variable among institutions and individual providers. The National Comprehensive Cancer Network r ... Full text Link to item Cite

Hepatic arterial melphalan perfusion of liver predominant uveal melanoma metastasis

Conference INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE · June 1, 2017 Link to item Cite

Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?

Journal Article Expert Opin Pharmacother · April 2017 Historically, there were few effective and durable treatments for metastatic melanoma. Recently, mutation based targeted therapies have revolutionized treatment and outcomes for patients with metastatic melanoma. Specifically, inhibitors aimed at BRAF, NRA ... Full text Link to item Cite

Computed Tomography-Based Limb Volume Measurements for Isolated Limb Infusion in Melanoma.

Journal Article Ann Surg Oncol · April 2016 BACKGROUND: Despite advances in cross-sectional imaging, chemotherapeutic dosing for isolated limb infusion (ILI) in melanoma is currently calculated through cumbersome and potentially imprecise manual measurements. The primary objective of this study was ... Full text Link to item Cite

Immune Checkpoint Inhibitor Therapy as a Novel and Effective Therapy for Aggressive Cutaneous Squamous-cell Carcinoma

Journal Article Clinical Skin Cancer · April 1, 2016 Background: Patients with metastatic or locally aggressive cutaneous squamous-cell carcinoma (cSCC) have historically had limited and noneffective treatment options. The mainstay treatment has been surgery, which can be disfiguring and may not be technical ... Full text Cite

Burden of disease predicts response to isolated limb infusion with melphalan and actinomycin D in melanoma.

Journal Article Ann Surg Oncol · February 2015 BACKGROUND: Isolated limb infusion (ILI) with melphalan is a minimally invasive, effective treatment for in transit melanoma. We hypothesized that burden of disease (BOD) would correlate to treatment response. METHODS: We retrospectively analyzed a prospec ... Full text Link to item Cite

Immunotherapy following regional chemotherapy treatment of advanced extremity melanoma.

Journal Article Ann Surg Oncol · August 2014 PURPOSE: Following regional chemotherapy (RC) for melanoma, approximately 75 % of patients will progress. The role of immunotherapy after RC has not been well established. METHODS: A prospective, single-institution database of 243 patients with in-transit ... Full text Link to item Cite

Age and gender differences in substance screening may underestimate injury severity: a study of 9793 patients at level 1 trauma center from 2006 to 2010.

Journal Article J Surg Res · May 1, 2014 BACKGROUND: Although the relationship between psychoactive substance use and injury is known, evidence remains conflicting on the impact of substance use on clinical outcomes after injury. We hypothesized that preinjury substance use would negatively impac ... Full text Link to item Cite

Hypoxia in melanoma: using optical spectroscopy and EF5 to assess tumor oxygenation before and during regional chemotherapy for melanoma.

Journal Article Ann Surg Oncol · May 2014 BACKGROUND: There is increasing evidence that tumor hypoxia plays a significant role in the chemoresistance of melanoma, but to our knowledge, real-time tumor oxygenation during isolated limb infusion (ILI) has not been studied. We sought to demonstrate th ... Full text Link to item Cite

Efficacy of repeat sentinel lymph node biopsy in patients who develop recurrent melanoma.

Journal Article J Am Coll Surg · April 2014 BACKGROUND: Even after negative sentinel lymph node biopsy (SLNB) for primary melanoma, patients who develop in-transit (IT) melanoma or local recurrences (LR) can have subclinical regional lymph node involvement. STUDY DESIGN: A prospective database ident ... Full text Link to item Cite

Discussion.

Journal Article J Am Coll Surg · April 2014 Full text Link to item Cite

Efficacy of Repeat Sentinel Lymph Node Biopsy in Patients Who Develop Recurrent Melanoma Discussion

Journal Article JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS · April 1, 2014 Link to item Cite

SRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma.

Journal Article Ann Surg Oncol · March 2014 BACKGROUND: Src kinase inhibition has been shown to augment the efficacy of chemotherapy. Dasatinib, a dual Src/Abl kinase inhibitor approved for the treatment of CML, is under investigation as monotherapy for tumors with abnormal Src signaling, such as me ... Full text Link to item Cite

Resection of residual disease after isolated limb infusion (ILI) is equivalent to a complete response after ILI-alone in advanced extremity melanoma.

Journal Article Ann Surg Oncol · February 2014 BACKGROUND: Isolated limb infusion (ILI) is a limb-preserving treatment for in-transit extremity melanoma. The benefit of resecting residual disease after ILI is unclear. METHODS: A multi-institutional experience was analyzed comparing patients who underwe ... Full text Link to item Cite

Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment.

Journal Article J Clin Invest · September 2013 Cancers subvert the host immune system to facilitate disease progression. These evolved immunosuppressive mechanisms are also implicated in circumventing immunotherapeutic strategies. Emerging data indicate that local tumor-associated DC populations exhibi ... Full text Open Access Link to item Cite

Melanoma

Journal Article · August 29, 2013 Full text Cite

Predicting disease progression after regional therapy for in-transit melanoma.

Journal Article JAMA Surg · June 2013 IMPORTANCE: Although approximately 30% to 50% of patients experience a complete response after regional chemotherapy for in-transit melanoma, a subset of patients will develop rapidly progressive disease. In the current era of an expanding armamentarium, i ... Full text Link to item Cite

Plasma cytokine analysis in patients with advanced extremity melanoma undergoing isolated limb infusion.

Journal Article Ann Surg Oncol · April 2013 BACKGROUND: Preprocedure clinical and pathologic factors have failed to consistently differentiate complete response (CR) from progressive disease (PD) in patients after isolated limb infusion (ILI) with melphalan for unresectable in-transit extremity mela ... Full text Link to item Cite

Simultaneous diaphragm and liver resection: a propensity-matched analysis of postoperative morbidity.

Journal Article J Am Coll Surg · March 2013 BACKGROUND: Although a concomitant diaphragm resection might be required at the time of hepatectomy to achieve tumor-free surgical margins, studies addressing its effect on postoperative morbidity and mortality have been inconclusive. The objective of this ... Full text Link to item Cite

Hepatic abscess

Chapter · January 1, 2013 Full text Cite

A multi-institution experience comparing the clinical and physiologic differences between upper extremity and lower extremity melphalan-based isolated limb infusion.

Journal Article Cancer · December 15, 2012 BACKGROUND: Although studies of melphalan-based isolated limb infusion (ILI) combine data from upper extremity (UE) treatments with those from lower extremity (LE) treatments, differences between the 2 may be clinically important. METHODS: Candidates for U ... Full text Link to item Cite

Melanoma

Chapter · November 15, 2012 Full text Cite

A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity.

Journal Article Ann Surg Oncol · November 2012 BACKGROUND: Isolated limb infusion with melphalan (ILI-M) corrected for ideal body weight (IBW) is a well-tolerated treatment for patients with in-transit extremity melanoma with an approximate 29 % complete response (CR) rate. Sorafenib, a multi-kinase in ... Full text Link to item Cite

A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma.

Journal Article Ann Surg · August 2012 OBJECTIVE/BACKGROUND: There is a high risk of relapse in stage IIIB/IIIC melanoma. The utility of 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography integrated with computed tomography (FDG-PET/CT) in these patients to evaluate response ... Full text Link to item Cite

Patterns of recurrence following complete response to regional chemotherapy for in-transit melanoma.

Journal Article Ann Surg Oncol · August 2012 BACKGROUND: Even after complete response (CR) to regional chemotherapy for in-transit melanoma, many patients develop recurrence. Understanding the probability, location, and timing of recurrences can optimize management strategies for this patient populat ... Full text Link to item Cite

Bevacizumab-induced alterations in vascular permeability and drug delivery: a novel approach to augment regional chemotherapy for in-transit melanoma.

Journal Article Clin Cancer Res · June 15, 2012 PURPOSE: To investigate whether the systemically administered anti-VEGF monoclonal antibody bevacizumab could improve regional chemotherapy treatment of advanced extremity melanoma by enhancing delivery and tumor uptake of regionally infused melphalan (LPA ... Full text Link to item Cite

A multi-institutional experience of repeat regional chemotherapy for recurrent melanoma of extremities.

Journal Article Ann Surg Oncol · May 2012 BACKGROUND: Hyperthermic isolated limb perfusion (HILP) or isolated limb infusion (ILI) are well-accepted regional chemotherapy techniques for in-transit melanoma of extremity. The role and efficacy of repeat regional chemotherapy for recurrence and which ... Full text Link to item Cite

Minimally invasive intra-arterial regional therapy for metastatic melanoma: isolated limb infusion and percutaneous hepatic perfusion.

Journal Article Expert Opin Drug Metab Toxicol · November 2011 INTRODUCTION: In-transit melanoma or melanoma presenting as unresectable liver metastases are clinical situations with limited therapeutic options. Regional intra-arterial therapies provide efficacious treatment alternatives for these patients. Through sur ... Full text Link to item Cite

Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution.

Journal Article J Am Coll Surg · August 2011 BACKGROUND: Hyperthermic isolated limb perfusion (HILP) and isolated limb infusion (ILI) are used to manage advanced extremity melanoma, but no consensus exists as to which treatment is preferable and how to monitor patients post-treatment. STUDY DESIGN: U ... Full text Link to item Cite

Limb preservation with isolated limb infusion for locally advanced nonmelanoma cutaneous and soft-tissue malignant neoplasms.

Journal Article Arch Surg · July 2011 OBJECTIVE: To demonstrate the efficacy of isolated limb infusion (ILI) in limb preservation for patients with locally advanced soft-tissue sarcomas and nonmelanoma cutaneous malignant neoplasms. BACKGROUND: Locally advanced nonmelanoma cutaneous and soft-t ... Full text Link to item Cite

Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma.

Journal Article J Clin Oncol · March 20, 2011 PURPOSE: Isolated limb infusion (ILI) with melphalan (M-ILI) dosing corrected for ideal body weight (IBW) is a well-tolerated treatment for patients with in-transit melanoma with a 29% complete response rate. ADH-1 is a cyclic pentapeptide that disrupts N- ... Full text Link to item Cite

Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.

Journal Article Mol Cancer Ther · July 2010 Melanoma responds poorly to standard chemotherapy due to its intrinsic chemoresistance. Multiple genetic and molecular defects, including an activating mutation in the BRaf kinase gene, are associated with melanoma, and the resulting alterations in signal ... Full text Link to item Cite

What's new in neoadjuvant therapy for breast cancer?

Book · 2010 Neoadjuvant treatment of breast cancer is currently being used in patients with advanced disease as well as with increasing application in those that present with initially operable breast cancer. The current clinical benefits of the use of NAC include: NA ... Full text Link to item Cite

Optimizing regional infusion treatment strategies for melanoma of the extremities.

Journal Article Expert Rev Anticancer Ther · November 2009 The incidence of malignant melanoma is increasing faster than any other cancer. In cases of recurrent melanoma confined to the extremities, hyperthermic isolated limb perfusion and isolated limb infusion provide a way to isolate the extremity and deliver a ... Full text Link to item Cite

A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma.

Journal Article Cancer · October 15, 2009 BACKGROUND: Isolated limb infusion with melphalan is a well-tolerated treatment for patients with in-transit extremity melanoma with an approximately 30% complete response (CR) rate. ADH-1 is a cyclic pentapeptide that disrupts N-cadherin adhesion complexe ... Full text Link to item Cite

Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis.

Journal Article Ann Surg Oncol · September 2009 BACKGROUND: Isolated limb infusion (ILI) is a minimally invasive technique delivering regional chemotherapy to treat in-transit extremity melanoma. Determining perioperative factors that could predict toxicity is important to optimize strategies to improve ... Full text Link to item Cite

Optimizing regional therapy for melanoma.

Journal Article Ann Surg Oncol · May 2009 Full text Link to item Cite

A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US.

Journal Article J Am Coll Surg · May 2009 BACKGROUND: Isolated limb infusion (ILI) is a minimally invasive approach for treating in-transit extremity melanoma, with only two US single-center studies reported. Establishing response and toxicity to ILI as compared with hyperthermic isolated limb per ... Full text Link to item Cite

Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity?

Journal Article Ann Surg Oncol · April 2009 BACKGROUND: This study aims to determine what effect correcting melphalan dosing for ideal body weight (IBW) has on toxicity and response in isolated limb infusion (ILI) in patients with advanced extremity melanoma. METHODS: This was an open observational ... Full text Link to item Cite

Surgical excision of infected arteriovenous grafts: technique and review.

Journal Article J Vasc Access · 2009 Infected prosthetic arteriovenous grafts for hemodialysis present a profound risk to patient well being. Here we present five recent cases and describe our technique for total graft excision. We also review the literature and discuss the much debated role ... Full text Link to item Cite

Current clinical and research approaches to optimizing regional chemotherapy: novel strategies generated through a better understanding of drug pharmacokinetics, drug resistance, and the development of clinically relevant animal models.

Journal Article Surg Oncol Clin N Am · October 2008 A common treatment modality for in transit melanoma of the extremity has been hyperthermic isolated limb perfusion (HILP) with melphalan and more recently, isolated limb infusion (ILI) with melphalan with or without dactinomycin. Research in the area has p ... Full text Link to item Cite

Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion.

Journal Article Ann Surg Oncol · August 2008 BACKGROUND: Isolated limb infusion (ILI) is a recently described minimally invasive technique developed in Australia for delivering regional chemotherapy. This study examined the efficacy and toxicity of ILI, compared to hyperthermic isolated limb perfusio ... Full text Link to item Cite

Future directions in regional treatment strategies for melanoma and sarcoma.

Journal Article Int J Hyperthermia · May 2008 Hyperthermic isolated limb perfusion (HILP) with melphalan and more recently isolated limb infusion (ILI) with melphalan +/- dactinomycin are common treatment modalities for both in-transit melanoma of the extremity and advanced extremity sarcoma. In order ... Full text Link to item Cite

Letter to the editor

Journal Article International Journal of Hyperthermia · January 2008 Full text Cite